The aim of the study was to evaluate feasibility and benefits of Bone Marrow Sparing IMRT over Standard IMRT. Materials and methods: It is a prospective, randomized study evaluating bone marrow sparing IMRT compared to standard IMRT. One hundred ninety two patients met the eligibility criteria, gave informed consent and were accrued as part of the study and randomized into two arms. They were treated with concurrent chemo radiation therapy and brachytherapy and evaluated for hematological toxicity at weekly intervals. Results: Our results show a significant difference in hemoglobin nadir, grade 2 and above hemoglobin toxicity in favour of bone marrow sparing arm. This may be more relevant in Indian scenario due to more prevalent anemia and low baseline hemoglobin. There was a difference observed in TLC nadir and grade 2 and above leukopenia in favour of bone marrow sparing but did not reach statistical significance. Our sample size was based on results from a retrospective analysis and our sample size might not have been sufficient for a prospective analysis. Our study was not powered enough to detect a difference in neutropenia between both arms, and as expected no significant difference was observed. There was no significant difference in need of growth factor support and PRBC transfusions between both arms, nor was there difference in number of chemotherapy cycles or treatment duration. Conclusions: Our results show that bone marrow sparing is feasible without compromising on target coverage or normal tissue sparing.